Navigation Links
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
Date:3/31/2009

PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has started in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV). Pharmasset filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) earlier this quarter.

"This is a significant milestone for Pharmasset. PSI-7851 is a wholly owned, second generation nucleotide analog that was discovered by Pharmasset scientists" stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "We continue to see nucleos(t)ide inhibitors as having the potential to be the cornerstone of future HCV treatment, given their higher barrier to resistance and antiviral activity across multiple HCV genotypes, characteristics that set them apart from other HCV drug classes. We look forward to reporting the first antiviral data with PSI-7851 in the second half of 2009."

About PSI-7851

PSI-7851 is a uridine nucleoside analog currently in developed for the treatment of chronic HCV infection. PSI-7851 has demonstrated in vitro anti-HCV activity with EC(50) values of 90 +/- 60 nM, which is approximately 15- to 20-fold more potent than the active metabolite of Pharmasset's first generation nucleoside polymerase inhibitor, R7128. In vitro studies of PSI-7851 have not shown evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is approximately 38 hours, which suggests the possibility for once-daily dosing. Like R7128, PSI-7851 has demonstrated in vitro activity against all of the most common HCV genotypes.

About Pharmasset'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal Year End 2008 Financial Results
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
4. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
8. Pharmasset Receives Notice of Allowance
9. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today reported net income for ... $5.09 per diluted share, and non-GAAP net income of $94.0 ... same period a year earlier was $93.3 million, or $0.81 ... or $0.84 per diluted share.  Net sales ...
(Date:7/29/2014)... 29, 2014 New technology in the form ... physicians to see and assess brain tissue more clearly ... study authors who released their findings today at the ... Meeting in Colorado Springs, CO. ... of neurointervention, a specialty that facilitates stroke treatment by ...
(Date:7/29/2014)... -- McGraw-Hill Education Professional, a leading global provider of ... communities, has announced the launch of the AccessMedicine ... world-renowned medical education platform. A key ... for download onto all iOS and Android devices, is ... to valuable AccessMedicine diagnostic resources in an ...
Breaking Medicine Technology:Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3
... Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... or "AOBO"), a pharmaceutical company dedicated to improving ... a broad range of prescription and over-the-counter ("OTC") ... Wujia Rongxue Oral Liquid, ("AWRO Liquid"), an OTC ...
... Nov. 11, 2010 Misonix, Inc. (Nasdaq: ... ultrasonic medical device technology, which worldwide is used for ... quarter ended September 30, 2010 financial results on Monday, ... Executive Officer and Richard Zaremba, Senior VP and Chief ...
Cached Medicine Technology:American Oriental Bioengineering Introduces Wujia Rongxue Oral Liquid 2Misonix Schedules First Quarter 2011 Financial Results Conference Call; November 15, 2010 at 4:30 P.M. Eastern 2
(Date:7/29/2014)... 30, 2014 Dignity Sciences Limited, a ... of a Phase I trial with DS107G, an oral ... study was a randomized, placebo-controlled, double-blind, single-ascending and multiple ... pharmacokinetics and effect of food on DS107G in healthy ... profile of DGLA following both single and multiple oral ...
(Date:7/29/2014)... have discovered a chemical alteration in a single human ... larger studies, could give doctors a simple blood test ... , The discovery, described online in The American ... gene involved in the function of the brain,s response ... what might otherwise be an unremarkable reaction to the ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... program was created by a holistic nutritional and functional medicine ... way of overcoming this problem. , Karen suffered from leaky ... so much time to develop this unique treatment. , ... her method, with sufferers from all around the world. The ...
(Date:7/29/2014)... Washington, New York (PRWEB) July 29, 2014 ... to protecting the rights of victims injured by defective ... lawsuit has been filed by plaintiffs in Canada who ... risk of cardiovascular events with the low testosterone ... filed on July 22, 2014 in the Ontario Superior ...
Breaking Medicine News(10 mins):Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3
... , , , , ... , , ROSEMONT, Ill., Aug. 3 A new ... of Bone and Joint Surgery (JBJS) finds that two years ... arthodesis (spine fusion) can be expected to have significant improvement in their ...
... , , , ST. LOUIS, ... tools such as Facebook, Twitter and YouTube are being used by ... Now, Anthem Blue Cross and Blue Shield members can add these ... insurer. In an effort to remain engaged and responsive to its ...
... 3 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. ... its Slavica BioChem division have reported results on ... Hyperbaric oxygenation (HBO) after traumatic brain injury have ... with doctors from the Hyperbaric Medical Center, School ...
... ... music by Jack Johnson, Ben Harper, Jason Mraz, G. Love & others , ... Los Angeles, CA (PRWEB) August 3, 2009 -- Domestix, a ... the Malibu Film Festival on Thursday, August 6th at the Malibu Cinemas. "Domestix is thrilled to ...
... Aug. 3 Pharmacy & Healthcare Communications, LLC announces the ... Times , a monthly journal that reaches the universe of ... as its website, www.PharmacyTimes.com , which has ... including Pharmacy Times Careers and ...
... injecting man-made, microscopic tubes into tumors and heating them with ... a way to effectively kill kidney tumors in nearly 80 ... potential future cancer treatment for humans. The study appears ... National Academy of Sciences ). It is the result of ...
Cached Medicine News:Health News:Neck Surgery for Cervical Spine Disorders Found to Alleviate Associated Headaches 2Health News:Neck Surgery for Cervical Spine Disorders Found to Alleviate Associated Headaches 3Health News:Anthem Blue Cross and Blue Shield in Missouri Harnesses Social Media to Interact with Members 2Health News:Anthem Blue Cross and Blue Shield in Missouri Harnesses Social Media to Interact with Members 3Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 2Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 3Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 4Health News:"Jesse's Story" to Open The 10th Annual Malibu Film Festival 2Health News:"Jesse's Story" to Open The 10th Annual Malibu Film Festival 3Health News:Pharmacy Times Names New Editorial Director 2Health News:Researchers effectively treat tumors with use of nanotubes 2Health News:Researchers effectively treat tumors with use of nanotubes 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: